|
|
|
| home > white papers > Value-Added Processing and Quality By Design Principles Help Meet High-Quality Demands - West Pharmaceutical Services, Inc. |
|
|
 WHITE PAPERS |
|
West Pharmaceutical Services, Inc.
|
|
Value-Added Processing and Quality By Design Principles Help Meet High-Quality Demands
|
|
The current pharmaceutical market has faced a variety of challenges,
including increasing expectations for quality from end-users and
regulatory agencies driven by concern for patient safety. While
pharmaceutical companies are working to assure that new quality and
compliance paradigms are met, a balance must be achieved between the
reality of managing costs in an effort to provide a product that meets
the requirements of payers along with facilitating profitability in
order to continue adequate business reinvestment.
|
|
|
|
|
|
|
 |
News and Press Releases |
 |
Sensitech Inc. Marks 30th Anniversary and Introduces New SensiWatchTM Platform for End-to-End Real-Time In-Transit Visibility
Beverly, MA, June 22, 2020 – For 30 years, Sensitech Inc. has helped
leading companies in the food, pharmaceutical, industrial and consumer
goods segmentsdeliver higher-quality products, ensure consumer safety,
comply with rigorous regulatory requirements, protect brand equity, and
increase profitability. Today,Sensitech builds on this legacy with the
announcement of a new state-of-the-art, end-to-end,real-time in-transit
visibility solution –the SensiWatchTMPlatform.Sensitech is part of
Carrier Global Corporation (NYSE: CARR), a leading global provider of
innovative heating, ventilating and air conditioning (HVAC),
refrigeration, fire, security and building automation technologies.
More info >> |
|
 |
White Papers |
 |
|
Accelerating the Time from DNA to Material
Merck
Cell line development is a critical step in upstream process development for monoclonal antibodies (mAbs). Unfortunately, the search for the bestproducing clone can be labor- and resource-intensive and is often compared with looking for a needle in a haystack. Cells must first be engineered to produce the biologic of interest and the cell line generated from a high producing clone must deliver a sufficiently high titer to support clinical studies, and ultimately commercialization of the therapeutic.
More info >> |
|
 |
Industry Events |
 |
Outsourcing in Clinical Trials Europe
26-27 October 2020, Paris, France
Arena International are delighted to announce the return of Outsourcing
in Clinical Trials Europe. Part of our global series of events, this
flagship show will attract the leading clinical professionals from
across Europe. The 10th Annual event will be hosted in Paris.
More info >> |
|
|
|
